Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia.
Akahoshi Y, Nakasone H, Takenaka K, Yamasaki S, Nakamura M, Doki N, Tanaka M, Ozawa Y, Uchida N, Ara T, Nakamae H, Ota S, Onizuka M, Yano S, Tanaka J, Fukuda T, Kanda Y, Atsuta Y, Kako S, Yanada M, Arai Y. Akahoshi Y, et al. Among authors: takenaka k. Blood Adv. 2023 Jun 27;7(12):2699-2708. doi: 10.1182/bloodadvances.2022009376. Blood Adv. 2023. PMID: 36661335 Free PMC article.
Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation.
Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K, Henzan H, Numata A, Ito Y, Takenaka K, Iwasaki H, Kamimura T, Eto T, Nagafuji K, Teshima T, Kato K, Akashi K. Shima T, et al. Among authors: takenaka k. Blood. 2013 Jan 31;121(5):840-8. doi: 10.1182/blood-2012-02-409607. Epub 2012 Dec 11. Blood. 2013. PMID: 23233661 Free article. Clinical Trial.
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T. Takenaka K, et al. Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26. Biol Blood Marrow Transplant. 2015. PMID: 26211985 Free article.
Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia.
Arai Y, Kondo T, Yamazaki H, Takenaka K, Sugita J, Kobayashi T, Ozawa Y, Uchida N, Iwato K, Kobayashi N, Takahashi Y, Ishiyama K, Fukuda T, Ichinohe T, Atsuta Y, Mori T, Teshima T; Japan Society for Hematopoietic Cell Transplantation. Arai Y, et al. Among authors: takenaka k. Haematologica. 2016 May;101(5):644-52. doi: 10.3324/haematol.2015.139469. Epub 2016 Feb 8. Haematologica. 2016. PMID: 26858357 Free PMC article.
Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.
Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji K, Kondo T, Shibayama H, Mori T, Usuki K, Azuma T, Tsutsumi Y, Tanaka J, Dairaku H, Matsuo K, Ozawa K, Kurokawa M, Arai S, Akashi K. Takenaka K, et al. Int J Hematol. 2017 Jan;105(1):59-69. doi: 10.1007/s12185-016-2102-3. Epub 2016 Oct 19. Int J Hematol. 2017. PMID: 27761702
Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.
Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, Ago H, Hirokawa M, Fukuda T, Atsuta Y, Kondo T. Murata M, et al. Among authors: takenaka k. Biol Blood Marrow Transplant. 2019 Aug;25(8):1536-1543. doi: 10.1016/j.bbmt.2019.02.019. Epub 2019 Mar 1. Biol Blood Marrow Transplant. 2019. PMID: 30826464 Free article. Clinical Trial.
Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type.
Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, Yasuhiro S, Ozawa Y, Katsuoka Y, Doki N, Sawa M, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H; Japan Society for Hematopoietic Cell Transplantation Transplantation-Related Complication Working Group. Yokoyama H, et al. Among authors: takenaka k. Biol Blood Marrow Transplant. 2020 Jul;26(7):1363-1370. doi: 10.1016/j.bbmt.2020.04.002. Epub 2020 Apr 18. Biol Blood Marrow Transplant. 2020. PMID: 32311477 Free article.
Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.
Onishi Y, Mori T, Yamazaki H, Takenaka K, Yamaguchi H, Shingai N, Ozawa Y, Iida H, Ota S, Uchida N, Miyamoto T, Katayama Y, Kato J, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y; Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Onishi Y, et al. Among authors: takenaka k. Ann Hematol. 2021 Jan;100(1):217-228. doi: 10.1007/s00277-020-04290-1. Epub 2020 Oct 9. Ann Hematol. 2021. PMID: 33033911
1,127 results